Prostate cancer with Gleason score of 4+3=7 is at least intermediate-risk, usually difficult to cure, and some studies say that the 5-year overall survival rate of non-metastatic patients is 92.9%, and the specific prognosis is related to the stage and the patient’s own situation. Prostate cancer is a common malignant tumor in elderly men, and its incidence has been rapidly increasing in China in recent years, and its causative factors have not been fully elucidated. Gleason classification is a widely used method for histological grading of prostate cancer, and Gleason classification, prostate-specific antigen (PSA) level and tumor stage are the most important indicators for deciding the treatment plan and prognosis. A Gleason score of 4+3 is at least intermediate risk, and high risk if PSA>20ng/ml or clinical stage>=T2c. For patients without distant metastases, some studies claimed that the 5-year biochemical recurrence-free rate after surgery for intermediate-risk, locally progression-free prostate cancer was 80.6%, the overall survival rate was 92.9%, the tumor-specific survival rate was 98.9%, and the biochemical recurrence-free survival rate was 79.3%. And patients with metastases had a poorer prognosis. Treatment is also correlated with patient prognosis and may be treated with radiotherapy, surgery, particle implantation, and endocrine therapy as appropriate. If prostate cancer is suspected or diagnosed, it is recommended to go to a regular hospital for a comprehensive evaluation of the condition and follow the doctor’s instructions for treatment to avoid delays.